BR112012006283A2 - formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte - Google Patents

formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte

Info

Publication number
BR112012006283A2
BR112012006283A2 BR112012006283A BR112012006283A BR112012006283A2 BR 112012006283 A2 BR112012006283 A2 BR 112012006283A2 BR 112012006283 A BR112012006283 A BR 112012006283A BR 112012006283 A BR112012006283 A BR 112012006283A BR 112012006283 A2 BR112012006283 A2 BR 112012006283A2
Authority
BR
Brazil
Prior art keywords
treating
preventing
adamts13 formulation
stabilized adamts13
methods
Prior art date
Application number
BR112012006283A
Other languages
English (en)
Other versions
BR112012006283B1 (pt
Inventor
H Peter Matthiessen
Hans-Peter Schwarz
Peter L Turecek
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of BR112012006283A2 publication Critical patent/BR112012006283A2/pt
Publication of BR112012006283B1 publication Critical patent/BR112012006283B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

''formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte.'' a presente invenção se refere a formulações de adamts13 com propriedades intensificadas ou desejáveis. como tal, a invenção fornece formulações líquidas e liofilizadas de adamts13 que são adequadas para administração farmacêutica. entre outros aspectos, a presente invenção também fornece métodos para tratar várias doenças e condições relacionadas com a disfunção de vwf e/ou adamts13 em um sujeito. também são fornecidos neste documento kits compreendendo formulações de adamts13 úteis para o tratamento de várias doenças e condições.
BR112012006283-2A 2009-09-21 2010-09-21 Formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e, usos de adamts13 BR112012006283B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24435309P 2009-09-21 2009-09-21
US61/244,353 2009-09-21
PCT/US2010/049723 WO2011035335A2 (en) 2009-09-21 2010-09-21 Stabilized liquid and lyophilized adamts13 formulations

Publications (2)

Publication Number Publication Date
BR112012006283A2 true BR112012006283A2 (pt) 2016-05-31
BR112012006283B1 BR112012006283B1 (pt) 2022-03-15

Family

ID=43598388

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006283-2A BR112012006283B1 (pt) 2009-09-21 2010-09-21 Formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e, usos de adamts13

Country Status (21)

Country Link
US (8) US8623352B2 (pt)
EP (4) EP3167897B1 (pt)
JP (2) JP5819303B2 (pt)
KR (5) KR20220139456A (pt)
CN (2) CN102573792B (pt)
AU (1) AU2010295299B2 (pt)
BR (1) BR112012006283B1 (pt)
CA (1) CA2774556A1 (pt)
DK (3) DK3834841T3 (pt)
EA (1) EA024267B1 (pt)
ES (3) ES2865250T3 (pt)
FI (1) FI3834841T3 (pt)
HK (1) HK1173968A1 (pt)
HR (1) HRP20160295T1 (pt)
HU (1) HUE028688T2 (pt)
IN (1) IN2012DN02645A (pt)
MX (3) MX362382B (pt)
NZ (1) NZ598839A (pt)
PL (3) PL2480198T3 (pt)
PT (1) PT3834841T (pt)
WO (1) WO2011035335A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101670103B1 (ko) 2008-12-05 2016-10-27 박스알타 인코퍼레이티드 폰빌레브란트 인자의 ａｄａｍｔｓ１３－매개 생체내 절단을 측정하는 방법 및 그의 사용
CN102573792B (zh) * 2009-09-21 2014-10-15 巴克斯特国际公司 稳定化的液体和冻干的adamts13制剂
NZ628126A (en) * 2012-02-16 2016-10-28 Atyr Pharma Inc Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
CN103566362B (zh) * 2012-07-21 2015-07-29 复旦大学 重组adamts13在制备脑出血药物中的用途
CA2890848C (en) * 2012-11-09 2020-11-17 Puget Sound Blood Center Protein stabilizing factors apolipoprotein a-1 or high density lipoprotein
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
EP3460054B1 (en) 2013-03-15 2020-10-21 aTyr Pharma, Inc. Histidyl-trna synthetase-fc conjugates
CA2952609A1 (en) * 2014-06-26 2015-12-30 Amgen Inc. Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
EP3401685B1 (en) 2016-01-08 2021-12-01 Kyoto University Diagnostic method and medicine comprising adamts13 as main ingredient
BR112019002194A2 (pt) * 2016-08-04 2019-05-21 Baxalta GmbH uso de adamts13 para tratar, melhorar e/ou prevenir a crise vaso-oclusiva na doença falciforme, lesão pulmonar aguda e/ou síndrome da insuficiência respiratória aguda
WO2018128689A1 (en) 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus formulations
US11767520B2 (en) 2017-04-20 2023-09-26 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
PL3639845T3 (pl) * 2017-07-25 2023-10-23 Jiangsu Hengrui Medicine Co., Ltd. Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania
CA3104196A1 (en) * 2018-07-11 2020-01-16 Baxalta Incorporated Aav compositions
US20230203469A1 (en) 2020-04-02 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
JP2023526546A (ja) 2020-05-22 2023-06-21 武田薬品工業株式会社 コロナウイルス疾患の合併症の治療及び診断のための、ａｄａｍｔｓ１３組成物及び方法
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
PT1154796E (pt) 1999-02-22 2007-09-28 Baxter Int Novas formulações de viii isentas de albumina
JP2001227510A (ja) 2000-02-15 2001-08-24 Tomoe Tech Res Co 複作動型の空気式アクチュエータ
JP3783507B2 (ja) 2000-02-16 2006-06-07 日本精工株式会社 トロイダル型無段変速機用ディスクの加工方法
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
ITPR20010055A1 (it) 2001-08-31 2003-03-03 Vetroarredo Spa Procedimento e impianto per la realizzazione di mattoni in vetro.
KR100472006B1 (ko) 2002-10-09 2005-03-10 동부아남반도체 주식회사 모스 트랜지스터 제조 방법
JP5112692B2 (ja) * 2003-07-07 2013-01-09 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル フォンビルブランド因子（ｖｗｆ）マルチマーを検出する方法およびシステム
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CA2606351C (en) 2005-06-17 2016-12-13 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
JP4880997B2 (ja) 2005-12-28 2012-02-22 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の安定化方法
CN101360820A (zh) 2006-01-04 2009-02-04 巴克斯特国际公司 无寡肽的细胞培养基
CN102573792B (zh) * 2009-09-21 2014-10-15 巴克斯特国际公司 稳定化的液体和冻干的adamts13制剂
US8823352B2 (en) 2011-07-11 2014-09-02 Linear Technology Corporation Switching power supply having separate AC and DC current sensing paths

Also Published As

Publication number Publication date
EP2480198A2 (en) 2012-08-01
MX2019000547A (es) 2020-11-12
US20170112906A1 (en) 2017-04-27
BR112012006283B1 (pt) 2022-03-15
CA2774556A1 (en) 2011-03-24
HK1173968A1 (zh) 2013-05-31
JP2015063556A (ja) 2015-04-09
US20140178357A1 (en) 2014-06-26
WO2011035335A3 (en) 2011-12-01
US20190247475A1 (en) 2019-08-15
CN102573792B (zh) 2014-10-15
EP3167897A1 (en) 2017-05-17
KR20180095738A (ko) 2018-08-27
CN102573792A (zh) 2012-07-11
ES2948612T3 (es) 2023-09-14
US10238720B2 (en) 2019-03-26
PT3834841T (pt) 2023-06-19
US8623352B2 (en) 2014-01-07
EA024267B1 (ru) 2016-09-30
EA201200519A1 (ru) 2012-09-28
EP3834841B1 (en) 2023-05-17
IN2012DN02645A (pt) 2015-09-11
PL3167897T3 (pl) 2021-09-27
KR20120099646A (ko) 2012-09-11
JP5819303B2 (ja) 2015-11-24
HUE028688T2 (en) 2017-01-30
CN104224705A (zh) 2014-12-24
EP2480198B1 (en) 2016-03-09
MX339205B (es) 2016-05-16
HRP20160295T1 (hr) 2016-05-20
US10758599B2 (en) 2020-09-01
EP4218797A1 (en) 2023-08-02
KR20220139456A (ko) 2022-10-14
FI3834841T3 (fi) 2023-06-05
US11564979B2 (en) 2023-01-31
US9937244B2 (en) 2018-04-10
ES2865250T3 (es) 2021-10-15
DK2480198T3 (en) 2016-03-29
US20180207245A1 (en) 2018-07-26
MX2012003414A (es) 2012-06-19
US9572778B2 (en) 2017-02-21
JP2013505270A (ja) 2013-02-14
DK3167897T3 (da) 2021-04-19
KR101891646B1 (ko) 2018-08-27
PL2480198T3 (pl) 2016-09-30
AU2010295299B2 (en) 2015-12-24
EP2480198B9 (en) 2016-11-23
PL3834841T3 (pl) 2023-07-24
KR20210054598A (ko) 2021-05-13
US20110229455A1 (en) 2011-09-22
US20200376098A1 (en) 2020-12-03
KR20190137954A (ko) 2019-12-11
AU2010295299A1 (en) 2012-04-12
NZ598839A (en) 2014-03-28
EP3167897B1 (en) 2021-01-27
MX362382B (es) 2019-01-14
DK3834841T3 (da) 2023-06-06
EP3834841A1 (en) 2021-06-16
US20160375111A1 (en) 2016-12-29
US20230130866A1 (en) 2023-04-27
WO2011035335A2 (en) 2011-03-24
CN104224705B (zh) 2018-02-02
ES2579906T3 (es) 2016-08-17
US9351935B2 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
ES2544967T3 (es) Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas
TW200637614A (en) Bendamustine pharmaceutical compositions
BR112014026703A2 (pt) inibidores de dna-pk
BR112015021888A2 (pt) inibidores de dna-ik
BR112012018386A8 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
WO2010083239A3 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
EA201001639A1 (ru) Композиции и способы их получения и применения
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
WO2007143607A3 (en) Method of treating atrophic vaginitis
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
MX2011009847A (es) Agentes antihelminticos y su uso.
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
EP4124346A3 (en) Compositions and methods for treating diseases
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
BR112012019921A2 (pt) composições líquidas compreendendo um agente de resfriamento não-metol e um espessante para tratamento de um sintoma respiratório.
EP3363454A3 (en) Treatment of diseases related to hyperactivity of the complement system
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: BAXTER INTERNATIONAL INC. (US) , BAXTER HEALTHCARE

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAXALTA INCORPORATED (US) ; BAXALTA GMBH (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/09/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.